XML 151 R94.htm IDEA: XBRL DOCUMENT v3.25.0.1
Principal alliances - Collaboration agreements on human therapeutic antibodies (Details)
€ in Millions, $ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 01, 2020
Jul. 01, 2015
agreement
Jul. 31, 2023
EUR (€)
Nov. 30, 2022
EUR (€)
Nov. 30, 2007
agreement
Mar. 31, 2022
Dec. 31, 2022
Rate
Dec. 31, 2024
EUR (€)
Rate
Dec. 31, 2023
EUR (€)
Rate
Dec. 31, 2023
USD ($)
Rate
Dec. 31, 2022
EUR (€)
bond
Dec. 31, 2022
USD ($)
bond
Dec. 31, 2015
Disclosure of detailed information about Principal Alliances [Line Items]                          
Net sales | €               € 41,081 € 37,817 [1]   € 37,651 [1]    
US                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Net sales | €               € 19,986 € 17,262 [2]   € 16,986 [3]    
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Number of agreements signed | agreement         2                
Phase III costs, responsibility percentage               80.00%          
Phase III costs, responsibility percentage for Regeneron               20.00%          
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)           10.00% 20.00%            
Percentage of cumulative development costs reimbursed               50.00%     50.00% 50.00%  
Period before scheduled launch date               24 months          
Number of payments | bond                     2 2  
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales of antibodies, first achievement                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Payment related to attainment of goal                       $ 50  
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales of antibodies, first achievement | Antibodies                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Net sales                       2,000  
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales of antibodies, second achievement                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Payment related to attainment of goal                       50  
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales of antibodies, second achievement | Antibodies                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Net sales                       $ 2,500  
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Prior agreement                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) | Rate             10.00% 10.00%          
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | New agreement                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) | Rate               20.00% 20.00% 20.00%      
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales Of Antibodies, Third Achievement                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Payment related to attainment of goal                   $ 50      
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Sales Of Antibodies, Third Achievement | Antibodies                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Net sales                   $ 3,000      
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | US                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Percentage of profits and losses arising from commercial operations               50.00%          
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Outside the United States                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Percentage of losses arising from commercial operations               55.00%          
Royalty expense, percentage (percentage) 5.00%                        
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Outside the United States | Bottom of range                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Percentage of profits arising from commercial operations               55.00%          
Regeneron Pharmaceuticals, INC | Antibodies Collaboration agreement | Outside the United States | Top of range                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Percentage of profits arising from commercial operations               65.00%          
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Number of agreements signed | agreement   2                      
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)                         10.00%
Percentage of cumulative development costs reimbursed                         50.00%
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement | Major Collaboration Agreement                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Proceeds from collaboration agreements | €               € 117 € 196   € 952    
AstraZeneca | Antibodies Collaboration agreement                          
Disclosure of detailed information about Principal Alliances [Line Items]                          
Collaboration agreements, regulatory milestone payment | €     € 65 € 25                  
Collaboration Agreements, Amount Paid | €               € 25          
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] (a)Figures for 2023 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3] (a)Figures for 2022 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.